retatrutide weight loss clinical trial Retatrutide, Eli Lilly's next generation of injections, showed dramatic results in trials, with patients losing an average of up to 71.2 pounds, or 28.7% of their body weight. Eli Discover - A new obesity

Biotech experts have called glucagon-like peptide-1 drugs (GLP-1s) the story of the decade

At 3 months and 6 months, they lost 5.9% and 10.9% of their body weight, respectively

When dizziness does occur, it is often transient and resolves with continued treatment, appropriate hydration, and management of contributing factors

The Small Business Innovation and Economic Security Act reauthorizes the SBIR/STTR programs through September 30, 2031, and introduces several significant changes to program administration

Wear loose clothing over the treated area

Try PatchMDs GLP-1 Extend Patch Ready to add convenient, needle-free metabolic support to your daily routine